We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Court Denies Request to Block Amgen, Allergan From Marketing Two Oncology Biosimilars
Federal Court Denies Request to Block Amgen, Allergan From Marketing Two Oncology Biosimilars
A federal judge in Delaware denied requests from Genentech to block the launch of biosimilars for its blockbuster treatments Avastin (bevacizumab) and Herceptin (trastuzumab). Following the court’s decision, Amgen and Allergan announced their products Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns) were available for sale.